Author

Игумнова Елена Николаевна

Observed names: E. N. Igumnova, Elena Igumnova, Elena N. Igumnova

Institution: Perm Regional Oncology Center

Observed institutions: University of Utah, Perm Regional Oncology Center, University of Utah Health Care

ORCID: 0009-0007-3428-9585

Observed ORCID: 0009-0007-3428-9585

OpenAlex ID: A5050939837

A Pathway for Community-Acquired Pneumonia With Rapid Conversion to Oral Therapy Improves Health Care Value

2020 · Claire E Ciarkowski, Tristan T Timbrook, et al. · Open Forum Infectious Diseases · 18

Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL).

2018 · Jordan P. McPherson, Shiven B. Patel, et al. · Journal of Clinical Oncology · 11

Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study

2024 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology · 2

Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma

2024 · M. I. Volkova, A. S. Kalpinskiy, et al. · Cancer Urology · 1

Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study

2025 · Maria I. Volkova, Alexey S. Kalpinskiy, et al. · Journal of Modern Oncology

Эффективность и безопасность ленватиниба с пембролизумабом при распространенном почечноклеточном раке в реальной практике: обновленные данные российского наблюдательного исследования

· Волкова Мария Игоревна, Калпинский Алексей Сергеевич, et al. · CyberLeninK (CyberLeninka)

Works count: 7

Citation count: 32

H-index: 2

I10-index: 2